on March 17, 2003
Published online before print March 17, 2003, doi: 10.1161/01.CIR.0000060544.41744.7C
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on November 11, 2002
From the Departments of Radiology and Cardiology, University Hospital Groningen (D.K., K.Y.J.A.M.H., R.V., M.O.); Bronovo Hospital, The Hague (D.K., P.R.M.v.D.), the Netherlands; and the Department of Cardiology, Leiden University Medical Center (P.R.M.v.D.), Leiden, the Netherlands. * To whom correspondence should be addressed. E-mail: kps{at}xs4all.nl.
Background--The purpose of this study was to assess the value of high-dose dobutamine cardiovascular magnetic resonance (CMR) with myocardial tagging for the detection of wall motion abnormalities as a measure of myocardial ischemia in patients with known or suspected coronary artery disease. Methods and Results--Two hundred eleven consecutive patients with chest pain underwent dobutamine-CMR 4 days after antianginal medication was stopped. Dobutamine-CMR was performed at rest and during increasing doses of dobutamine. Cine-images were acquired during breath-hold with and without myocardial tagging at 3 short-axis levels. Regional wall motion was assessed in a 16-segment short-axis model. Patients with new wall motion abnormalities (NWMA) were examined by coronary angiography. Dobutamine-CMR was successfully performed in 194 patients. Dobutamine-CMR without tagging detected NWMA in 58 patients, whereas NWMA were detected in 68 patients with tagging (P=0.002, McNemar). Coronary angiography showed coronary artery disease in 65 (96%) of these 68 patients. All but 3 of the 65 patients needed revascularization. In the 112 patients with a negative dobutamine-CMR study, without baseline wall motion abnormalities, the cardiovascular occurrence-free survival rate was 98.2% during the mean follow-up period of 17.3 months (range, 7 to 31). Conclusions--Dobutamine-CMR with myocardial tagging detected more NWMA compared with dobutamine-CMR without tagging and reliably separated patients with a normal life expectancy from those at increased risk of major adverse cardiac events.
Revised on January 7, 2003
Accepted on January 14, 2003
Dobutamine Cardiovascular Magnetic Resonance for the Detection of Myocardial Ischemia With the Use of Myocardial Tagging
Dirkjan Kuijpers MD*,
Key words: magnetic resonance imaging • myocardium • stress • ischemia
This article has been cited by other articles:
 |
|
 |
|
  G. Korosoglou, D. Lossnitzer, D. Schellberg, A. Lewien, A. Wochele, T. Schaeufele, M. Neizel, H. Steen, E. Giannitsis, H. A. Katus, et al. Strain-Encoded Cardiac MRI as an Adjunct for Dobutamine Stress Testing: Incremental Value to Conventional Wall Motion Analysis Circ Cardiovasc Imaging, March 1, 2009; 2(2): 132 - 140. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Potter, P. A. Araoz, K. P. McGee, W. S. Harmsen, J. N. Mandrekar, and T. M. Sundt III Low-dose dobutamine cardiac magnetic resonance imaging with myocardial strain analysis predicts myocardial recoverability after coronary artery bypass grafting. J. Thorac. Cardiovasc. Surg., June 1, 2008; 135(6): 1342 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J.W. Gotte, T. Germans, I. K. Russel, J. J.M. Zwanenburg, J. T. Marcus, A. C. van Rossum, and D. J. van Veldhuisen Myocardial Strain and Torsion Quantified by Cardiovascular Magnetic Resonance Tissue Tagging: Studies in Normal and Impaired Left Ventricular Function J. Am. Coll. Cardiol., November 21, 2006; 48(10): 2002 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, L. Sun, Y. Huan, H. Zhao, and J. Deng Effects of basic fibroblast growth factor microspheres on angiogenesis in ischemic myocardium and cardiac function: analysis with dobutamine cardiovascular magnetic resonance tagging. Eur. J. Cardiothorac. Surg., July 1, 2006; 30(1): 103 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Paetsch, C. Jahnke, V. A. Ferrari, F. E. Rademakers, P. A. Pellikka, W. G. Hundley, D. Poldermans, J. J. Bax, K. Wegscheider, E. Fleck, et al. Determination of interobserver variability for identifying inducible left ventricular wall motion abnormalities during dobutamine stress magnetic resonance imaging Eur. Heart J., June 2, 2006; 27(12): 1459 - 1464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Paetsch, C. Jahnke, E. Fleck, and E. Nagel Current clinical applications of stress wall motion analysis with cardiac magnetic resonance imaging Eur J Echocardiogr, October 1, 2005; 6(5): 317 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Paetsch, D. Foll, A. Kaluza, R. Luechinger, M. Stuber, A. Bornstedt, A. Wahl, E. Fleck, and E. Nagel Magnetic resonance stress tagging in ischemic heart disease Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2708 - H2714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Pennell, U. P. Sechtem, C. B. Higgins, W. J. Manning, G. M. Pohost, F. E. Rademakers, A. C. van Rossum, L. J. Shaw, and E. K. Yucel Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report Eur. Heart J., November 1, 2004; 25(21): 1940 - 1965. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Wahl, I. Paetsch, S. Roethemeyer, C. Klein, E. Fleck, and E. Nagel High-Dose Dobutamine-Atropine Stress Cardiovascular MR Imaging after Coronary Revascularization in Patients with Wall Motion Abnormalities at Rest Radiology, October 1, 2004; 233(1): 210 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Jérôm. Garot The study of diastole by tagged MRI: are we nearly there yet? Eur. Heart J., August 2, 2004; 25(16): 1376 - 1377. [Full Text] [PDF]
|
|
|
|
|
|
H. S. Maniar, B. P. Cupps, D. D. Potter, P. Moustakidis, C. J. Camillo, C. M. Chu, M. K. Pasque, and T. M. Sundt III Ventricular function after coronary artery bypass grafting: Evaluation by magnetic resonance imaging and myocardial strain analysis J. Thorac. Cardiovasc. Surg., July 1, 2004; 128(1): 76 - 82. [Abstract] [Full Text] [PDF]
|
|